Skip to content

European Medicines Agency’s (EMA) Committee For Orphan Medicinal Products (COMP) November 2012 Meeting Results

November 14, 2012

                    EMA’s Committee for Orphan Medicinal Products (COMP) held a meeting November 6 – 7, 2012.   

        The EMA COMP November 2012 Meeting Report on the review of applications for orphan designation is published November 8, 2012.  At the November 2012 EMA COMP meeting, there are 13 positive opinions recommending orphan designation for the treatment of:

– peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
– acromegaly
– non-infectious uveitis
– chronic lymphocytic leukaemia
– perinatal asphyxia
– malaria
– lead toxicity
– Duchenne muscular dystrophy (2 products)
– chronic lymphocytic leukaemia
– malignant mesothelioma
– long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
– very long-chain acyl-CoA dehydrogenase deficiency.

         The remaining COMP 2012 Meeting Schedule is as follows :   

         –  December  5 – 6, 2012. 

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: